Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients.
Zhanyi LiYing LiuYing ZhangXiaoqiong ShaoQiumin LuoXiaoyan GuoGuoli LinQingxian CaiZhixin ZhaoYutian ChongPublished in: BioMed research international (2017)
RAVs to DAAs preexist in treatment-naive HCV-6a patients. Further studies should address the issue of the impact of RAVs in response to DAA therapies for HCV-6a patients.